SALIM VIRANI to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications SALIM VIRANI has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.505
-
Cardiovascular Disease Prevention in Focus: Highlights from the 2019 American Heart Association Scientific Sessions. Curr Atheroscler Rep. 2020 01 11; 22(1):3.
Score: 0.128
-
Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session. Curr Atheroscler Rep. 2019 05 24; 21(8):31.
Score: 0.122
-
The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know. Curr Atheroscler Rep. 2019 04 02; 21(6):20.
Score: 0.121
-
Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs. Circulation. 2017 06 20; 135(25):2572-2574.
Score: 0.106
-
Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project. Am Heart J. 2018 01; 195:151-152.
Score: 0.027